Imdelltra is associated with improvement in overall survival compared to local standard-of-care chemotherapy among patients with small cell lung cancer.

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Doctors stage non-small cell lung cancer (NSCLC) according to how far it has progressed. Stages range from occult (or hidden) cancer to stage 4 cancer, in which multiple organs may be affected.

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

J Clin Oncol. 2022;40 (6): 671-680. 6 Dingemans AC, Fruh M, Ardizzoni A et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

may improve the prognostic value for overall survival and could help inform treatment decisions in Non Small Cell Lung Cancer (NSCLC); and how Volition's Nu.Q® H3.1, low-cost immunoassay may be ...

For years, the default definitive treatment for patients with early-stage I non–small cell lung cancer (NSCLC ... and the European Society for Medical Oncology all list surgery (in particular ...

ELCC is a program of the European Society for Medical Oncology (ESMO ... development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). Telomeres, along with the enzyme telomerase ...